Merck’s Heart Failure Drug Flunks Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.
You may also be interested in...
Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline
The mid-January announcement that Merck & Co. was ending one pivotal trial and removing patients with a history of stroke from another for Phase III anti-clotting agent vorapaxar has called into question the pharma’s continued heavy emphasis on cardiovascular research and development.
Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline
The mid-January announcement that Merck & Co. was ending one pivotal trial and removing patients with a history of stroke from another for Phase III anti-clotting agent vorapaxar has called into question the pharma’s continued heavy emphasis on cardiovascular research and development.
Where Are They Now? Checking In On Four Cardiovascular Start-Ups
It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.